BAJAJHCARE · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 5/100 — Quality 11 · Valuation 0 · Momentum 0
| Share price | ₹386.55 |
| Market cap | ₹1,174 Cr |
| P/E ratio | 51.8 |
| P/B ratio | 2.1 |
| ROE | 93.7% |
| ROCE | 8.7% |
| Dividend yield | 0.29% |
| Book value | ₹167.01 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹611 Cr | ₹16 Cr | 12.6% |
| 2025 | ₹543 Cr | ₹40 Cr | 10.0% |
| 2024 | ₹473 Cr | ₹-84 Cr | 10.3% |
| 2023 | ₹646 Cr | ₹43 Cr | 14.6% |
| 2022 | — | — | — |
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antio